v3.21.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
REVENUES:    
Product revenue $ 42,076,949 $ 29,206,249
License revenue 142,834 142,834
Total revenues 42,219,783 29,349,083
OPERATING EXPENSES:    
Cost of product revenue (exclusive of amortization expense shown below) 61,291,426 39,504,238
Research and development 5,907,013 2,343,848
Plasma center operating expenses 4,170,051 2,169,629
Amortization of intangible assets 715,353 844,938
Selling, general and administrative 35,050,817 25,910,757
Total operating expenses 107,134,660 70,773,410
LOSS FROM OPERATIONS (64,914,877) (41,424,327)
OTHER INCOME (EXPENSE):    
Interest income 288,126 800,785
Interest expense (11,985,066) (8,993,379)
Gain (loss) on extinguishment of debt 991,797 (9,962,495)
Gain on transfer of plasma center assets 0 11,527,421
Other expense (128,528) (227,322)
Other expense, net (10,833,671) (6,854,990)
NET LOSS $ (75,748,548) $ (48,279,317)
BASIC AND DILUTED LOSS PER COMMON SHARE $ (0.88) $ (0.89)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:    
Basic and Diluted 86,145,052 54,348,136

Source